Abstract 406P
Background
Adrenal insufficiency (AI) is one of the immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs). Although the incidence of ICI-induced AI is low, delayed diagnosis of AI could lead to serious outcomes such as adrenal crisis. Few studies have described the detailed clinical features of this rare, but potentially life-threatening irAE.
Methods
We retrospectively reviewed 145 patients (pts) who developed AI during treatment with ICIs from October 2015 to March 2021 at the multicenter. The pts’ clinical characteristics and laboratory and radiologic findings were collected.
Results
The characteristics were as follows: median age, 68 years (range, 30-85); male/female, 104/41; treatment anti-PD-1/anti-PD-L1/anti-PD-1 plus anti-CTLA-4, 109/6/26. The median time of clinical diagnosis was 4.7 months (range, 0.5-34.7), and the median number of ICI administrations before onset was 6 times (range, 1-60).Enlarged pituitary gland on MRI were noted in 11 pts (7.6%). Among these, 8 pts were under treatment with anti-PD-1 plus anti-CTLA-4 and 3 pts were under treatment with anti-PD-1. Symptoms at the onset of AI included anorexia in 84 pts (58%), and fatigue in 78 pts (54%). As laboratory findings, hyponatremia was observed in 59 pts (41%), and eosinophilia was seen in 56 pts (39%). The median serum cortisol and plasma ACTH levels at diagnosis were 1.40 μg/dL (range, 0.05-30.90) and 3.70 pg/mL (range, 0.5-177.0), respectively. Among 138 pts in which both ACTH and cortisol levels were available, 136 pts (99%) had secondary AI, while only 2 pts (1%) had primary AI. Other endocrinopathies seen in these cases included type 1 diabetes mellitus in 5 pts (3.4%), thyroid dysfunction in 30 pts (21%).
Conclusions
In this study, almost all of the ICI-induced AI cases were secondary to ACTH deficiency. Affected patients showed similar symptoms and findings to those of general AI, but those were not always present. In most cases, AI occurred within the 6 months and the diagnosis was made before the onset of overt symptoms by regular measurement of ACTH and cortisol levels. So, it is important that we should measure ACTH and cortisol levels regularly at least during the first 6 months for early detection.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
462P - Limited duration of treatment with checkpoint inhibitors in complete responders, yet prolonged survival: A real-world study from India
Presenter: Nitin Murthy
Session: Poster viewing 06
463P - Cost effectiveness of palbociclib and ribociclib in metastatic breast cancer in India using ICER and QALY
Presenter: Krishnamani Kalpathi
Session: Poster viewing 06
464TiP - Phase III study of adjuvant encorafenib plus binimetinib vs placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design
Presenter: Alexander van Akkooi
Session: Poster viewing 06
465TiP - Evaluation of quality of life and functional outcomes following limb salvage surgery in extremities sarcomas
Presenter: naveen kushwaha
Session: Poster viewing 06
YO2 - A case of locally advanced breast cancer with biomarker conversion successfully treated with neoadjuvant chemotherapy-immunotherapy combination
Presenter: Long Nguyen
Session: Poster viewing 06
YO3 - Metastatic Breast cancer to esophagus: A case report and review of literature
Presenter: Bhuvana J
Session: Poster viewing 06
YO4 - Succinate Dehydrogenase deficient GISTs is a diagnostic and therapeutic dilemma? : A case report.
Presenter: Nurazzahra Kamarudin
Session: Poster viewing 06
YO5 - Complete Radiologic and Pathologic Response in a Metastatic Gallbladder Adenocarcinoma Patient treated with Checkpoint Inhibitor/Chemotherapy Combination: A Case Report
Presenter: Tisha Gay Tancongco
Session: Poster viewing 06
YO7 - Orbital Metastasis in Prostrate Cancer: A Case Report
Presenter: Shabnam Rehman
Session: Poster viewing 06
YO10 - BRCA2 Mutated Recurrent Adult Granulosa Cell Tumor Treated with PARP Inhibitor
Presenter: Debapriya Mondal
Session: Poster viewing 06